| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SAR1B |
| Uniprot No | Q9Y6B6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSFIFDW IYSGFSSVLQ FLGLYKKTGK LVFLGLDNAG KTTLLHMLKD DRLGQHVPTL HPTSEELTIA GMTFTTFDLG GHVQARRVWK NYLPAINGIV FLVDCADHER LLESKEELDS LMTDETIANV PILILGNKID RPEAISEERL REMFGLYGQT TGKGSISLKE LNARPLEVFM CSVLKRQGYG EGFRWMAQYI D |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SAR1B重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：**"Structural basis of Sar1B-mediated protein cargo selection by the COPII complex"**
**作者**：Mancias, J.D., Goldberg, J.
**摘要**：该研究通过X射线晶体学解析了SAR1B重组蛋白与COPII复合体结合的结构，揭示了SAR1B在识别内质网分泌蛋白中的关键作用，并阐明了其GTP酶活性调控货物分选的分子机制。
---
2. **文献名称**：**"Functional characterization of SAR1B mutations in chylomicron retention disease"**
**作者**：Sane, A., et al.
**摘要**：作者利用重组SAR1B蛋白进行体外功能实验，发现疾病相关突变(如G14R、D137N)会导致GTP结合/水解能力缺陷，破坏COPII囊泡形成，从而解释患者肠道脂质转运障碍的病理机制。
---
3. **文献名称**：**"Recombinant SAR1B expression and purification for biochemical analysis of COPII assembly"**
**作者**：Bi, X., et al.
**摘要**：该文献建立了一种高效的大肠杆菌表达系统，纯化获得功能性SAR1B重组蛋白，并通过体外重构实验证明其与Sec23/24复合体的相互作用是COPII囊泡形成的必要条件。
---
这些研究涵盖了SAR1B的结构、功能及疾病关联，为理解其在细胞内运输中的作用提供了关键依据。
**Background of SAR1B Recombinant Protein**
SAR1B is a member of the SAR1 GTPase family, critical for intracellular protein trafficking via COPII-coated vesicles. These vesicles mediate transport of newly synthesized proteins and lipids from the endoplasmic reticulum (ER) to the Golgi apparatus. SAR1B, specifically, regulates COPII assembly by cycling between an inactive GDP-bound state and an active GTP-bound form. Upon GTP binding, SAR1B recruits other COPII components (e.g., Sec23/24. Sec13/31) to form vesicles, enabling cargo packaging and ER export.
SAR1B is distinct from its paralog SAR1A due to tissue-specific expression; SAR1B is highly expressed in enterocytes and hepatocytes, where it plays a key role in lipid metabolism. Mutations in the *SAR1B* gene are linked to chylomicron retention disease (CMRD), a rare autosomal recessive disorder characterized by defective lipid absorption, leading to malnutrition and vitamin deficiencies. Studying SAR1B aids in understanding molecular mechanisms of lipid transport and CMRD pathogenesis.
Recombinant SAR1B protein is produced using expression systems (e.g., *E. coli* or mammalian cells) to generate purified, functional protein for research. It enables in vitro studies on COPII vesicle formation, GTPase activity, and interactions with cargo receptors or chaperones. Additionally, recombinant SAR1B is used to screen therapeutic compounds targeting lipid metabolism disorders or to develop assays for diagnosing CMRD. Structural studies leveraging recombinant SAR1B (e.g., X-ray crystallography) have revealed conformational changes during GTP hydrolysis, providing insights into its regulatory role in vesicle budding.
Overall, SAR1B recombinant protein serves as a vital tool for dissecting ER-Golgi trafficking mechanisms and advancing therapeutic strategies for related metabolic diseases.
×
